Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: iStock
The recent hantavirus outbreak aboard the luxury ship MV Hondius, which drew global attention and raised concerns about the potential for wider spread, has highlighted the need for better therapeutics and vaccines.
The outbreak claimed three lives and infected 13 people. While those affected recovered from the infection, they had contracted the Andes strain, which carries a risk of human-to-human transmission. There is currently no specific antiviral drug or vaccine for the Andes virus.
Now, researchers writing in The Lancet Infectious Diseases have reported early promising results for tocilizumab as a treatment for severe hantavirus pulmonary syndrome (HPS).
The researchers said tocilizumab warrants further evaluation as a treatment for severe hantavirus pulmonary syndrome.
Also read: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say
The study is based on a case series involving 10 hantavirus patients treated at Hospital Zonal de Bariloche, Argentina, between June 1, 2024, and May 6, 2026.
Tocilizumab is an immunosuppressive medication used to treat severe inflammatory conditions, including severe COVID-19 and autoimmune diseases such as rheumatoid arthritis.
Researchers from San Carlos de Bariloche, Argentina, said that under an ethical framework allowing the emergency use of unproven medications outside clinical trials when no satisfactory alternatives exist, tocilizumab was administered to five eligible patients with laboratory-confirmed severe hantavirus pulmonary syndrome.
Five other patients received standard supportive care without Tocilizumab because they were too sick or the medication was unavailable when treatment was being considered. The case series represents the first descriptive report from a larger ongoing study.
Four of the five patients treated with Tocilizumab survived and were discharged from intensive care, whereas all five patients who did not receive Tocilizumab died shortly after admission to intensive care.
There is currently no approved vaccine or specific antiviral treatment for the Andes strain, underscoring the importance of further research into potential therapies such as tocilizumab.
However, the authors said, "the findings should not be interpreted as evidence for the implementation of routine use of Tocilizumab to treat severe hantavirus pulmonary syndrome, but they do support the need for urgent further research".
According to the World Health Organization (WHO), hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans.
Globally, an estimated 100,000 to 200,000 hantavirus infections occur each year. The majority of cases are reported in Asia, particularly China. Most infections are sporadic or occur in small clusters linked to contact with infected rodents.
In humans, hantavirus infection can cause severe illness and death, although disease severity varies depending on the virus strain and geographical region.
Hantavirus pulmonary syndrome is a severe viral disease caused by the Andes virus, a type of hantavirus endemic in several regions of the Americas, including Argentina and Chile. In recent years, parts of Argentina have seen an increase in hantavirus cases.
The severe respiratory illness can rapidly become fatal. Reported fatality rates range from 20 per cent to 40 per cent, depending on the outbreak setting, quality of medical care, and surveillance capacity.
Hantavirus is primarily spread through contact with infected rodents, including exposure to:
Credit: iStock
Unsafe food causes around 866 million illnesses and 1.5 million deaths annually, according to new estimates released by the World Health Organization (WHO) ahead of World Food Safety Day 2026.
The analysis warned that children aged less than five years face almost three times the risk of illness from unsafe food than older children and adults.
Children under 5 years of age experience 29 per cent of the health burden due to unsafe food, with 143,000 deaths in 2021, said the WHO. The global health body added that exposure to chemical hazards such as methylmercury and lead in food can harm the developing brain and cause lifelong neurological and developmental problems in children.
Foodborne diseases in children, particularly diarrhoeal diseases, can be deadly for this vulnerable age group.
“Food safety is not an abstract issue – it touches every meal, every family, every day. Unsafe food has always been a major public health concern, but until now we lacked the bigger picture of its staggering human and economic toll. These new estimates change that,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.
“For the first time, countries have their own data to see where the burden is highest. With that knowledge, governments can prioritize the actions needed to protect people’s health,” he added.
Also read: FSSAI Introduces Stricter Quality Checks For Besan, Seafood, And Edible Oils: What You Should Know
The WHO noted that exposure to biological hazards, including foodborne bacteria, viruses and parasitic infections, caused the majority of foodborne illnesses (approximately 860 million in 2021), while chemical exposures accounted for 73 per cent of deaths.
The new analysis significantly expands the evidence base by assessing 42 major foodborne hazards, including bacteria, viruses, parasites and chemicals, across 194 countries from 2000 to 2021.
The estimates now include new hazards such as metals, rotavirus and Trypanosoma cruzi, the parasite that causes Chagas disease.
Food can also be contaminated with chemicals such as inorganic arsenic, lead and methylmercury from natural sources and human activities.
The estimates revealed for the first time that dietary exposure to metals is increasing the burden of:
Other risk factors include:
Read More: Worried About Weight Gain After Wegovy, Mounjaro? This US FDA-Approved Daily Pill May Help
Yuki Minato, WHO technical officer for food safety and senior author of The Lancet Global Health paper, noted that the analysis shows foodborne diseases are “being made worse by climate change, which increases contamination risks, and by antimicrobial resistance, which makes infections harder to treat”.
Yuki called for “a One Health approach – integrating human, animal, plant and environmental health” to save lives.
The WHO estimates that many food-related illnesses and deaths are preventable through measures including:
Credit: AI Generated Image
Prostate cancer is a big issue now in the United Kingdom, as the nation is witnessing 64,000 men diagnosed and 12,000 dying each year from this deadly disease. The statistics show that one in eight men will get prostate cancer in their lifetime, but for black men, that risk doubles to one in four.
As a preventive measure to find better ways of testing for the disease, tens of thousands of black men are invited for prostate cancer checks as part of an ongoing trial where the age group is between 45 and 74.
This crucial move has been taken after the minister considered the UK National Screening Committee's recent recommendation that most men should not be offered regular testing for the disease.
The committee stressed that the blood test for detecting prostate cancer, called PSA, is more harmful than its benefits, except for a few men who have a dangerous genetic variant and a family history of cancer.
The government is proactive about this major health issue and stated that it will invest 18 million pounds to transform the trial.
The research aims to determine whether other tests and procedures, alongside PSA, can be used in the screening process. In this study, they will check whether genetic checks and faster MRI scans can be used with greater accuracy,
Health Secretary James Murray said, "This is a major step forward in how we tackle prostate cancer - focusing on those most at risk, improving the treatments available, and backing the research we need to close the evidence gaps and save lives."
Also Read: Donald Trump: As President Boasts Cognitive Test Score - Truth Social Posts Suggest Otherwise
The prostate is a small walnut-shaped gland in men that produces seminal fluid, which nourishes and transports sperm. Prostate cancer develops when abnormal cells begin growing in the gland.
Though not all prostate cancers are life-threatening. Some forms grow very slowly and may never affect a man’s lifespan. Such slow-growing cancers are found in around one in three men over the age of 50.
However, a smaller number of prostate cancers are aggressive, spread rapidly, and can become life-threatening, making timely detection important.
Also Read: Prostate Cancer Screening In UK To Focus On High-Risk Men; Guidelines Reject Universal Testing
Screening typically involves a blood test called prostate-specific antigen (PSA). Depending on the results, patients may then undergo an MRI scan of the prostate.
However, screening healthy men can sometimes lead to overdiagnosis and unnecessary treatment, which may result in side effects such as erectile dysfunction and loss of bladder control.
A major review by the National Screening Committee found that for every 1,000 men screened in their 50s, two prostate cancer deaths could be prevented over 15 years.
But the same screening could also result in 20 men being diagnosed with cancers that would never have required treatment. Of those 20 men, 12 could undergo unnecessary treatment that may damage the prostate, affect sexual function, or cause urinary incontinence.
© 2024 Bennett, Coleman & Company Limited